Trillium Asset Management LLC Sells 40 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Trillium Asset Management LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.7% during the fourth quarter, HoldingsChannel reports. The firm owned 667 shares of the medical equipment provider’s stock after selling 40 shares during the period. Trillium Asset Management LLC’s holdings in Intuitive Surgical were worth $348,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ISRG. Atala Financial Inc bought a new position in Intuitive Surgical in the 4th quarter worth about $25,000. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the fourth quarter worth approximately $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical during the 4th quarter worth $28,000. Kohmann Bosshard Financial Services LLC bought a new stake in Intuitive Surgical during the 4th quarter valued at $31,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Intuitive Surgical in the 4th quarter worth $36,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $492.06 on Thursday. Intuitive Surgical, Inc. has a fifty-two week low of $364.17 and a fifty-two week high of $616.00. The firm has a market capitalization of $175.26 billion, a PE ratio of 76.76, a P/E/G ratio of 5.85 and a beta of 1.43. The stock’s 50-day simple moving average is $564.39 and its 200-day simple moving average is $531.62.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ISRG shares. Truist Financial decreased their price objective on Intuitive Surgical from $666.00 to $605.00 and set a “buy” rating for the company in a report on Monday. UBS Group upped their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Royal Bank of Canada upped their target price on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Finally, Leerink Partners lifted their price target on Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $611.86.

Insider Buying and Selling

In other Intuitive Surgical news, CFO Jamie Samath sold 269 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $590.00, for a total value of $158,710.00. Following the sale, the chief financial officer now directly owns 3,282 shares of the company’s stock, valued at approximately $1,936,380. This represents a 7.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at $6,955,015. The trade was a 27.41 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,754 shares of company stock worth $17,691,621. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.